- Home
- ARCL vs PLX Comparison
ARCL vs PLX Comparison
Compare ARCL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$3.12
Company Overview
Basic Information| Metric | ARCL | PLX |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 207.1M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARCL | PLX |
|---|---|---|
| Price | $10.02 | $3.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 31.5K | ★ 777.4K |
| Earning Date | N/A | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.88 | $1.65 |
| 52 Week High | $10.10 | $3.19 |
Technical Indicators
Market Signals| Indicator | ARCL | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 71.58 |
| Support Level | $9.96 | $2.18 |
| Resistance Level | N/A | $3.19 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 33.33 | 100.00 |
Price Performance
Historical Comparison ARCL
PLX
About ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.